Mem Inst Oswaldo Cruz, Rio de Janeiro, VOLUME 119 | 2024
Perspective
Advances in the development of new vaccines for tuberculosis and Brazil’s role in the effort forward the end TB strategy
1Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Rede Goiana de Pesquisa em Tuberculose, Goiânia, GO, Brasil
2Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brasil
3Universidade Federal do Mato Grosso do Sul, Faculdade de Medicina, Mato Grosso do Sul, MS, Brasil
4Fundação Oswaldo Cruz-Fiocruz, Mato Grosso do Sul, MS, Brasil
5Yale School of Public Health, New Haven, CT, USA
6Instituto Adolfo Lutz, Núcleo de Tuberculose e Micobacterioses, São Paulo, SP, Brasil
7Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Rio de Janeiro, RJ, Brasil
8Universidade de São Paulo, Escola de Enfermagem de Ribeirão Preto, Ribeirão Preto, SP, Brasil
9Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil
DOI: 10.1590/0074-02760240093
ABSTRACT
Tuberculosis (TB) continues to be the world’s leading killer of infectious diseases. Despite global efforts to gradually reduce the number of annual deaths and the incidence of this disease, the coronavirus disease 19 (COVID-19) pandemic caused decreased in TB detection and affected the prompt treatment TB which led to a setback to the 2019 rates. However, the development and testing of new TB vaccines has not stopped and now presents the possibility of implanting in the next five years a new vaccine that is affordable and might be used in the various key vulnerable populations affected by TB. Then, this assay aimed to discuss the main vaccines developed against TB that shortly could be selected and used worldwide, and additionally, evidence the Brazilian potential candidates’ vaccines in developing in Brazil that could be considered among those in level advanced to TB end.
REFERENCES
01. WHO - World Health Organization. Global tuberculosis report 2023. Available from: https://www.who.int/teams/global-tuberculosis- programme/tb-reports/global-tuberculosis-report-2023.
02. da Costa, C, Onyebujoh P, Thiry G, Zumla A. Advances in development of new tuberculosis vaccines. Curr Opin Pulm Med. 2023; 29(3): 143-8.
03. WHO - World Health Organization. WHO preferred product characteristics for new tuberculosis vaccine. 2018. Available from: https://www.who.int/publications/i/item/WHO-IVB-18.06.
04. Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG, et al. 100 years of Mycobacterium bovis bacille Calmette- Guérin. Lancet Infect Dis. 2022; 22(1): e2-e12.
05. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271: 698-702.
06. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014; 58(4): 470-80.
07. Martinez L, Cords O, Liu Q, Acuna-Villaorduna C, Bonnet M, Fox GJ, et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob Health. 2022; 10: e1307-16.
08. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 2005; 366(9493): 1290-5.
09. Dantas OM, Ximenes RA, de Albuquerque MF, da Silva NL, Montarroyos UR, de Souza WV, et al. A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. Int J Tuberc Lung Dis. 2006; 10(5): 536-41.
10. Barreto ML, Pilger D, Pereira SM, Genser B, Cruz AA, Cunha SS, et al. Causes of variation in BCG vaccine efficacy: examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses. Vaccine. 2014; 32(30): 3759-64.
11. Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018; 379: 138-49.
12. WHO - World Health Organization. BCG vaccines: WHO position paper – February 2018. Geneva: World Health Organization. 2018. Available from: https://www.who.int/publications/i/item/ who-wer9308-73-96.
13. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and metaanalysis. BMJ. 2014; 349: g4643.
14. Scriba TJ, Netea MG, Ginsberg AM. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Sem Immunol. 2020; 50: 101431.
15. Pelzer PT, Smit Y, Tiemersma EW, Huong NT, Nhung NV, Cobelens F. Does BCG vaccination protect against infection with M. tuberculosis? Int J Tuberc Lung Dis. 2022; 26(6): 529-36.
16. Lancione S, Alvarez JV, Alsdurf H, Pai M, Zwerling AA. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas. BMJ Glob Health. 2022; 7(1): e007462.
17. McShane H. Revaccination with BCG: does it work? Lancet Infect Dis. 2024; 24(6): 559-60.
18. Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hesseling AC, et al. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines. 2014; 13(5): 619-30.
19. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, t al. The recombinant Bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol. 2017; 8: 1147.
20. Loxton AG, Knaul JK, Grode L, Gutschmidt A, Meller C, Eisele B, et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol. 2017; 24(2): e00439-16.
21. Dockrell HM. A next generation BCG vaccine moves forward. Lancet Infect Dis. 2022; 22(10): 1404-6.
22. Díaz C, Pérez Del Palacio J, Valero-Guillén PL, Mena García P, Pérez I, Vicente F, et al. Comparative metabolomics between Mycobacterium tuberculosis and the MTBVAC vaccine candidate. ACS Infect Dis. 2019; 5(8): 1317-26.
23. Martín C, Marinova D, Aguiló N, Gonzalo-Asensio J. MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG. Vaccine. 2021; 39(50): 7277-85.
24. Lacámara S, Martin C. MTBVAC: a tuberculosis vaccine candidate advancing towards clinical efficacy trials in TB prevention. Arch Bronconeumol. 2023; 59(12): 821-8.
25. Dijkman K, Aguilo N, Boot C, Hofman SO, Sombroek CC, Vervenne RAW, et al. Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Rep Med. 2021; 2(1): 100187.
26. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein1. J Immunol. 2004; 172(12): 7618-28.
27. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr Opin Immunol. 2012; 24(3): 310-5.
28. Gillard P, Yang P-C, Danilovits M, Su W-J, Cheng S-L, Pehme L, et al. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study. Tuberculosis. 2016; 100: 118-27.
29. Kumarasamy N, Poongulali S, Bollaerts A, Moris P, Beulah FE, Ayuk LN, et al. A randomized, controlled safety, and immunogenicity trial of the M72/AS01 candidate tuberculosis vaccine in HIV-positive Indian adults. Medicine. 2016; 95: e2459.
30. Thacher EG, Cavassini M, Audran R, Thierry A-C, Bollaerts A, Cohen J, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS. 2014; 28: 1769-81.
31. Tait DR, Hatherill M, van der Meeren O, Ginsberg AM, van Brakel E, Salaun B, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019; 381(25): 2429-39.
32. Wilson L, Gracie L, Kidy F, Thomas GN, Nirantharakumar K, Greenfield S, et al. Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials. BMC Infect Dis. 2023; 23(1): 120.
33. Idoko OT, Owolabi OA, Owiafe PK, Moris P, Odutola A, Bollaerts A, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis. 2014; 6: 564-78.
34. Vasina DV, Kleymenov DA, Manuylov VA, Mazunina EP, Koptev EY, Tukhovskaya EA, et al. First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: safety and immunogenicity assessment. Vaccines. 2019; 7(4): 166.
35. Tkachuk AP, Gushchin VA, Potapov VD, Demidenko AV, Lunin VG, Gintsburg AL. Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One. 2017; 12(4): e0176784.
36. Tkachuk AP, Bykonia EN, Popova LI, Kleymenov DA, Semashko MA, Chulanov VP, et al. safety and immunogenicity of the Gam- TBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines. 2020; 8(4): 652.
37. Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. npj Vaccines. 2018; 3: 34.
38. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 2011; 6(1): e16333.
39. Baldwin SL, Reese VA, Huang PW, Beebe EA, Podell BK, Reed SG, et al. Protection and long-lived immunity induced by the ID93/ GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate. Clin Vaccine Immunol. 2015; 23(2): 137-47.
40. Kwon KW, Lee A, Larsen SE, Baldwin SL, Coler RN, Reed SG, et al. Long-term protective efficacy with a BCG-prime ID93/GLASE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci Rep. 2019; 9: 15560.
41. Munseri P, Said J, Amour M, Magohe A, Matee M, Rees CA, et al. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial. Vaccine. 2020; 38(46): 7239-45.
42. Lahey T, Laddy D, Hill K, Schaeffer J, Hogg A, Keeble J, et al. Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. PLoS One. 2016; 11(12): e0168521.
43. von Reyn CF, Lahey T, Arbeit RD, Landry B, Kailani L, Adams LV, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. PLoS One. 2017; 12(5): e0175215.
44. Masonou T, Hokey DA, Lahey T, Halliday A, Berrocal-Almanza LC, Wieland-Alter WF, et al. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial. PLoS One. 2019; 14(5): e0217091.
45. Dogra S, Jain S, Sharma A, Chhabra S, Narang T. Mycobacterium Indicus Pranii (MIP) vaccine: pharmacology, indication, dosing schedules, administration, and side effects in clinical practice. Indian Dermatol Online J. 2023; 14(6): 753-61.
46. Gupta A, Saqib M, Singh B, Pal L, Nishikanta A, Bhaskar S. Mycobacterium indicus pranii induced memory t-cells in lung airways are sentinels for improved protection against M. tb infection. Front Immunol. 2019; 10: 2359.
47. Bonato VL, Lima VM, Tascon RE, Lowrie DB, Silva CL. Identification and characterization of protective T cells in hsp65 DNAvaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun. 1998; 66(1): 169-75.
48. Lima KM, Bonato VL, Faccioli LH, Brandão IT, dos Santos SA, Coelho-Castelo AA, et al. Comparison of different delivery systems of vaccination for the induction of protection against tuberculosis in mice. Vaccine. 2001; 19(25-26): 3518-25.
49. Ruberti M, De Melo LK, Dos Santos SA, Brandao IT, Soares EG, et al. Prime-boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention. J Drug Target. 2004; 12(4): 195-203.
50. Silva CL, Bonato VL, Coelho-Castelo AA, De Souza AO, Santos SA, Lima KM, et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther. 2005; 12(3): 281-7.
51. de Lima MR, Leandro ACCS, de Souza AL, Barradas MM, Roma EH, Fernandes ATG, et al. Safety and immunogenicity of an in vivo muscle electroporation delivery system for DNA-hsp65 tuberculosis vaccine in cynomolgus monkeys. Vaccines. 2023; 11(12): 1863.
52. Teixeira FM, Teixeira HC, Ferreira AP, Rodrigues MF, Azevedo V, Macedo GC, et al. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vaccine Immunol. 2006; 13(8): 930-5.
53. de Castro CP, Souza BM, Mancha-Agresti P, Pereira VB, Zurita- Turk M, Preisser TM, et al. Lactococcus lactis FNBPA+ (pValac:e6ag85a) induces cellular and humoral immune responses after oral immunization of mice. Front Microbiol. 2021; 12: 676172.
54. Carlétti D, da Fonseca DM, Gembre AF, Masson AP, Weijenborg Campos L, Leite LCC, et al. A single dose of a DNA vaccine encoding apa coencapsulated with 6,6’-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice. Clin Vaccine Immunol. 2013; 20(8): 1162-9.
55. Rizzi C, Peiter AC, Oliveira TL, Seixas Neto ACP, Leal KS, Hartwig DD, et al. Stable expression of Mycobacterium bovis antigen 85B in auxotrophic M. bovis bacillus Calmette-Guérin. Mem Inst Oswaldo Cruz. 2017; 112(2): 123-30.
56. Rizzi C, Bianco MV, Blanco FC, Soria M, Gravisaco MJ, Montenegro V, et al. Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. PLoS One. 2012; 7(12): e51396.
57. Araújo-Filho JA, Vasconcelos Jr AC, Sousa EM, Silveira C, Ribeiro E, Kipnis A, et al. Extensively drug-resistant tuberculosis: a case report and literature review. Braz J Infect Dis. 2008; 12(5): 447-52.
58. Silva BDS, Trentini MM, da Costa AC, Kipnis A, Junqueira-Kipnis AP. Different phenotypes of CD8+ T cells associated with bacterial load in active tuberculosis. Immunol Lett. 2014; 160(1): 23-32.
59. Limongi LC, Olival L, Conde MB, Junqueira-Kipnis AP. Determination of levels of specific IgA to the HspX recombinant antigen of Mycobacterium tuberculosis for the diagnosis of pleural tuberculosis. J Bras Pneumol. 2011; 37(3): 302-7.
60. Zagmignan A, Costa ACD, Viana JL, Lima Neto LG, Monteiro CA, Gaioso Neto AG, et al. Identification of specific antibodies against the Ag85C-MPT51-HspX fusion protein (CMX) for serological screening of tuberculosis in endemic area. Expert Rev Clin Immunol. 2017; 13(8): 837-43.
61. de Sousa EM, da Costa AC, Trentini MM, de Araújo Filho JA, Kipnis A, Junqueira-Kipnis AP. Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection. PLoS One. 2012; 7(10): e47781
62. Junqueira-Kipnis AP, Souza CC, Carvalho ACO, de Oliveira FM, Almeida VP, de Paula AR, et al. Protease-based subunit vaccine in mice boosts BCG protection against Mycobacterium tuberculosis. Vaccines. 2022; 10(2): 306.
63. Santos BPO, Trentini MM, Machado RB, Celes MRN, Kipnis A, Petrovsky N, et al. Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection. Hum Vaccin Immunother. 2017; 13(12): 2967-76.
64. da Costa AC, Costa-Júnior AO, de Oliveira FM, Nogueira SV, Rosa JD, Resende DP, et al. A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis. PLoS One. 2014; 9(11): e112848.
65. de Oliveira FM, Trentini MM, Junqueira-Kipnis AP, Kipnis A. The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosis compared to Bacillus Calmette-Guérin but with similar lung inflammatory effects. Mem Inst Oswaldo Cruz. 2016; 111(4): 223-31.
66. Nascimento IP, Rodriguez D, Santos CC, Amaral EP, Rofatto HK, Junqueira-Kipnis AP, et al. Recombinant BCG expressing LTAK63 adjuvant induces superior protection against Mycobacterium tuberculosis. Sci Rep. 2017; 7(1): 2109.
67. Dos Santos CC, Rodriguez D, Issamu AK, Leite LCC, Nascimento IP. Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria. Hum Vaccin Immunother. 2020; 16(3): 673-83.
68. Moraes L, Trentini MM, Fousteris D, Eto SF, Chudzinski-Tavassi AM, Leite LCC, et al. CRISPR/Cas9 approach to generate an auxotrophic BCG strain for unmarked expression of LTAK63 adjuvant: a tuberculosis vaccine candidate. Front Immunol. 2022; 13: 867195.
69. Marques-Neto LM, Trentini MM, Kanno AI, Rodriguez D, Leite LCC. Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against Mycobacterium tuberculosis challenge in mice. Front Immunol. 2023; 14: 1205449.
Financial support: CNPq. APJK, ACCC and RAA are research fellows of CNPq (#311128/2023-8; #307014/2022-3; 311399/2022-3), RAA also the Funding for global events - CNPQ (446825/2023-9).
+ Corresponding author: ana_kipnis@ufg.br 
https://orcid.org/0000-0002-4200-6617
Received 24 April 2024
Accepted 04 September 2024
HOW TO CITE
Junqueira-Kipnis AP, Leite LCC, Croda J, Chimara E, Carvalho ACC, Arcêncio RA. Advances in the development of new vaccines for tuberculosis and Brazil’s role in the effort forward the end TB strategy. Mem Inst Oswaldo Cruz. 2024; 119: e240093.
